CompletedNCT00363376
A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
Medication studyAges 18+United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- MasonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 42
- Sponsor
- Lindner Center of HOPE
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00363376
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
Get this study by email
Recruitment & locations
CompletedMason
Questions about this study
Who is behind this study?
The study sponsor is Lindner Center of HOPE.
Did this study involve medication?
Yes. The study involved medication, including zonisamide, olanzapine, Zonisamide and Sugar Pill (placebo).
Who was this study for?
Listed age limits: from 18 years.
